adalimumab and anti-CCP antibodies Archives

Abstract Number: 471 • ACR/ARHP Annual Meeting 2015
Impact of Baseline Anti-Cyclic Citrullinated Peptide 2 Antibody Titer on Efficacy Outcomes Following Treatment with Subcutaneous Abatacept or Adalimumab
Jeremy Sokolove¹, M Schiff², Roy Fleischmann³, Michael Weinblatt⁴, SE Connolly⁵, A Johnsen⁵, J Zhu⁵, MA Maldonado⁵, S Patel⁵ and WH Robinson⁶, ¹Stanford University School of Medicine, Palo Alto, CA, ²University of Colorado, Denver, CO, ³University of Texas Southwestern Medical Center, Dallas, TX, ⁴Brigham and Women's Hospital, Boston, MA, ⁵Bristol-Myers Squibb, Princeton, NJ, ⁶Medicine, Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA
Background/Purpose: In patients (pts) with RA, the predictive value of baseline (BL) titers of anti-citrullinated protein antibodies (ACPA), a known biomarker for RA and disease…

Abstracts tagged "adalimumab and anti-CCP antibodies"